Kelly Sean G, Campbell Toby C, Hillman Luke, Said Adnan, Lucey Michael R, Agarwal Parul D
Ohio State University, Gastroenterology, Hepatology and Nutrition - Columbus, OH, USA.
University of Wisconsin, Oncology and Palliative Medicine - Madison, WI, USA.
Ann Hepatol. 2017 May-Jun;16(3):395-401. doi: 10.5604/16652681.1235482.
Utilization of palliative care services in patients dying of end-stage liver disease (ESLD) is understudied. We performed a retrospective review of palliative care services among patients with ESLD unsuitable for liver transplantation (LT) at a tertiary care center.
Deceased ESLD patients considered unsuitable for LT from 2007-2012 were identified. Patients were excluded if they received a transplant, had an incomplete workup, were lost to follow up or whose condition improved so LT was not needed. Of the 1,175 patients reviewed, 116 met inclusion criteria.
Forty patients (34.4%) received an inpatient palliative care (PC) consultation and forty-one patients (35.3%) were referred directly to hospice. Thirty-three patients (28.4%) transitioned to comfort measures without PC consultation (median survival < 1 day). The median interval between LT denial and PC consultation or hospice was 28 days. Median survival after PC consult or hospice referral was 15 days. In conclusion, in a single center retrospective review of ESLD patients, palliative care services, when utilized, were for care at the very end of life. Without consultation, aggressive interventions continued until hours before death. We propose that ESLD patients could benefit from PC consultation at time of LT evaluation or based on MELD scores.
对于终末期肝病(ESLD)临终患者姑息治疗服务的利用情况研究不足。我们对一家三级医疗中心中不适合肝移植(LT)的ESLD患者的姑息治疗服务进行了回顾性研究。
确定2007年至2012年期间被认为不适合LT的已故ESLD患者。如果患者接受了移植、检查不完整、失访或病情改善不再需要LT,则将其排除。在审查的1175例患者中,116例符合纳入标准。
40例患者(34.4%)接受了住院姑息治疗(PC)会诊,41例患者(35.3%)被直接转诊至临终关怀机构。33例患者(28.4%)未经过PC会诊就过渡到了舒适措施(中位生存期<1天)。LT被拒绝与PC会诊或临终关怀之间的中位间隔时间为28天。PC会诊或临终关怀转诊后的中位生存期为15天。总之,在对ESLD患者进行的单中心回顾性研究中,姑息治疗服务在被利用时,是用于生命末期的护理。未经会诊时,积极的干预措施一直持续到死亡前数小时。我们建议ESLD患者在LT评估时或根据终末期肝病模型(MELD)评分接受PC会诊可能会受益。